GEHC — GE HealthCare Technologies Inc.

The stock is down 11.55% over the past month and 7.16% in the past week as of 2026-09-13, sitting just above its 52-week low of $58.75. Despite Q2 2026 revenue growth of 5.8% YoY and EPS of $1.24 (+17% YoY), investors are focused on the negative Q2 free cash flow of -$617M, the CFO transition, persistent China weakness, and inflation-driven margin volatility. Analyst consensus remains Buy with a $78.73 target, but price action and RSI at 28.25 show the market is not yet buying the recovery story.

Revenue has grown from roughly $4.6B-$5.2B per quarter in 2023 to $5.295B in Q2 2026, but the path is uneven. YoY growth was around 0-2% in 2024, improved to 3-6% in 2025, then showed a sharp split in 2026: Q1 revenue rose 7.4% YoY but operating income fell 18.1% and EPS dropped 30.9% to $0.85, while Q2 revenue rose 5.8% YoY and EPS jumped 17.0% to $1.24. Gross margin in Q2 2026 expanded to 41.2% from 39.7% a year earlier, but Q1 2026 gross margin compressed to 38.5% from 42.1%. FCF swung to -$617M in Q2 2026 from +$8M in Q2 2025, a major red flag. The trend is best described as a volatile stabilization with a positive Q2 inflection, not a clean structural acceleration; the record $23.9B backlog and 11.1% organic order growth are forward supports that trailing numbers do not yet reflect.

As of 2026-09-13, the price of $63.93 gives GEHC a TTM P/E of 18.37 versus its 5-year average of 17.48, so trailing valuation is slightly rich. However, on forward earnings, the stock is cheap: next-FY consensus EPS of $4.925 implies a forward P/E of roughly 13.0x, well below the 5-year average of 17.48x. P/S is 1.426 versus a 5-year average of 1.68, and EV/EBITDA is 10.65. The negative PEG ratio reflects trailing earnings declines, but if estimates are met, the forward multiple offers a clear discount to the company's own history and to the analyst target of $78.73.

The market is pricing GEHC as if forward EPS of $4.925 is unlikely to be delivered. At $63.93, the stock trades at ~13.0x forward EPS, while the 5-year average P/E is 17.48x and analyst targets cluster at $75.83-$78.73. If Q3 2026 confirms backlog conversion, margin recovery, and positive free cash flow, a re-rating to 15-17x forward EPS would imply $74-$84. If Q3 instead shows another negative FCF quarter or further margin compression, estimates could be cut and the current multiple would prove fair or even optimistic. This is a binary show-me setup.

As of 2026-09-13, RSI stood at 28.25, which is oversold. The price of $63.93 was 9.88% below the SMA20, 6.4% below the SMA50, and 11.9% below the SMA200, with the 52-week range at $58.75-$89.77. The trend is clearly down, and while oversold conditions can produce a mean-reversion bounce, there is no reversal signal yet. Entry-timing implication: waiting for price to reclaim the SMA20 or form a higher low would reduce the risk of catching a falling knife.

• Inflation in electronic components, memory chips, freight, and commodities continues to pressure gross margins, though management says pricing and efficiencies are offsetting over half of the headwinds.
• China hospital procurement dynamics and tighter equipment checks are causing structural YoY revenue declines, only partially offset by U.S. and EMEA demand.
• Tariff and trade policy uncertainty remains, with retroactive IEEPA refunds providing modest bottom-line insulation but no permanent margin relief.
• Hospital capital budgets are sensitive to interest rates; higher-for-longer rates could delay large imaging and ultrasound equipment purchases.
• Healthcare sector rotation and medtech sentiment are mixed, with investors favoring defensive names but punishing companies that miss cash-flow or margin expectations.

• Q3 2026 earnings release (expected late October/early November 2026), focusing on whether the record $23.9B backlog converts to revenue and whether free cash flow turns positive.
• Closure and integration of the rumored ~$1B Sofie Biosciences acquisition, which would expand GEHC's radiopharmaceutical and PET diagnostics footprint.
• FDA clearance progress for the StarGuide GX 4D SPECT/CT theranostics system and commercial traction for newly launched Photonova Spectra and Vivid ultrasound products.
• Execution under new permanent CFO William Grogan, including any updates to capital allocation, guidance, or cost-reduction plans.
• Potential China stimulus or procurement recovery that could reverse the current regional revenue drag.

• Cash flow deterioration: Q2 2026 operating cash flow was -$517M and free cash flow was -$617M; if this persists, it would limit buybacks, dividends, and debt reduction.
• Margin volatility: Q1 2026 operating margin fell to 10.0% from 13.2% a year earlier, and Q4 2025 net income dropped 74% YoY to $184M.
• China revenue decline and structural procurement headwinds that could continue to offset growth in the U.S. and EMEA.
• High leverage and tight liquidity: long-term debt of $10.1B, current ratio of 1.02, and quick ratio of 0.721 as of 2026-06-30.
• Execution risk around the Sofie Biosciences acquisition, CFO transition, and competitive pressure from Siemens Healthineers, Philips, and Canon in imaging and ultrasound.

As of 2026-09-13, GEHC is a show-me story. The record $23.9B backlog, 11.1% organic order growth, and ~13x forward P/E are genuinely attractive if estimates hold, but negative Q2 free cash flow, volatile margins, China weakness, and a clear technical downtrend keep the risk/reward skewed to the downside. The stock may be undervalued if Q3 proves cash conversion and margin recovery, but until that evidence arrives, I would not call it a buy.

Applied a 15.0x P/E multiple to next-FY consensus EPS of $4.925, a discount to GEHC's 5-year average TTM P/E of 17.48x to reflect mid-single-digit growth, China headwinds, and recent FCF volatility, but above the current ~13.0x forward multiple. 4.925 * 15.0 = $73.88.